Discontinued drug projects in the respiratory therapeutic area during 2012

Expert Opinion on Investigational Drugs

Volumn 23, Issue 3, 2014, Pages 411-415

  Snell, Noel J C ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Clinical trials; Drugs; Lung fibrosis; Pulmonary hypertension

Indexed keywords

ANIMALS; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; HUMANS; LUNG DISEASES; RESPIRATORY SYSTEM AGENTS; TREATMENT OUTCOME;

EID: 84894053517     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.873785     Document Type: Review

References (34)

1. Fajt M, Gelhaus S, Freeman B, et al. Prostaglandin D2 pathway upregulation: Relation to asthma severity, control, and Th2 inflammation. J Allergy Clin Immunol 2013;131:1504-12
2. Pettipher R, Whittaker M. Update on the development of antagonists of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2). From lead optimization to clinical proof-of-concept in asthma and allergic rhinitis. J Med Chem 2012;55:2915-31
3. Diamant Z, Singh D, O'Connor BJ, et al. Effect of multiple-dose setipiprant, a selective oral CRTH2 antagonist, on allergen-induced airway responses in allergic asthmatic patients. Am J Respir Crit Care Med 2012;185:A3957
4. Press release, Actelion. 2012. Available from: Http://www. actelion.com/en/our-company/news-Andevents/ index.page?newsId=1598979) [Last accessed 24 November 2013]
5. Company presentation, Roche. 2012.slide 68 Available from: Http:// www.roche.com/irp2q12e.pdf [Last accessed 24 November 2013]
6. Snell N, Foster M, Vestbo J. Efficacy and safety of AZD1981, a CRTh2 receptor antagonist, in patients with moderate to severe COPD. Respir Med 2013;107:1722-30
7. Krenitsky V, Nadolny L, Delgado M, et al. Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorg Med Chem Lett 2012;22:1433-8
8. Kluwe J, Pradere J-P, Gwak G-Y, et al. Modulation of Hepatic Fibrosis by c-Jun-N-terminal Kinase Inhibition. Gastroenterology 2010;138:347-59
9. Flynn C, Cheung-Flynn J, Smoke C, et al. Internalization and intracellular trafficking of a PTD-conjugated antifibrotic peptide, AZX100, in human dermal keloid fibroblasts. J Pharm Sci 2010;99:3100-21
10. Pini A, Viappiani S, Calosi L, et al. Effects of NCX 226, a compound targeting endothelin receptors and NO pathway, on bleomycin-induced lung inflammation and fibrosis in the mouse. Ann Rheum Dis 2011;70(Suppl 3):490
11. Struthers M, Pasternak A. CCR2 antagonists. Curr Top Med Chem 2010;10:1278-98
12. Available from: Http://www. astrazenecaclinicaltrials.com/ mshost800325/content/clinical-trials/ resources/pdf/D3320C00002 [Last accessed 23 November 2013
13. Press release, Orexo. 2012.Pages 2 & 4 Available from: Http:// feed.ne.cision.com/wpyfs/00/00/00/00/ 00/18/0D/87/wkr0001.pdf [Last accessed 28 September 2013]
14. Lam B. Leukotriene C4 synthase. Prostaglandins Leukot Essent Fatty Acids 2003;69:111-16
15. Cartwright H. AstraZeneca to evaluate orexo respiratory programme previously partnered with Janssen. Pharma Deals Review 2013(2):14
16. Fuentes M, Ma X, Zhang J, et al. Anti-tSLPR antibody RG7258 blocks dendritic cell activation, mast cell cytokine release and reduces Th2 inflammation in a non-human primate model of allergic lung inflammation. Am J Respir Crit Care Med 2011;183:A2767
17. Busse W, Wenzel S, Meltzer E, et al. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. J Allergy Clin Immunol 2013;131:339-45
18. Hall I, Sarno M, Disse B, et al. Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid. Eur Respir J 2012;40(Suppl 56):312s 19. Eberhardt C, Klopfenstein N, Larsen P, et al. ARRY-502, a potent and selective CRTh2 antagonist, affects basophil and eosinophil function both in vitro and in vivo. Am J Respir Crit Care Med 2011;183:A4353
19. Experimental asthma drug meets main goal in mid-stage study. Medscape; Available from: Www.medscape.com [Last accessed 23 July 2013]
20. Singh D, Cadden P, Hunter M, et al. Inhibition of the asthmatic allergen challenge response by the CRTh2 antagonist OC000459. Eur Respir J 2013;41:46-52
21. Barnes N, Pavord I, Chuchalin A, et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy 2012;42:38-48
22. Fitzgerald M, Whitmarsh M, Prosser J, et al. The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma. Eur Respir J 2013;42:137s
23. Fitzgerald M, Snape S, Febbraro S, et al. The safety, PK and PD profile of ADC3680, a potent and selective CRTh2 antagonist, in healthy volunteers and partly controlled atopic asthmatic subjects. Eur Respir J 2013;42:697s
24. Wells A, Behr J, Costabel U, et al. Triple therapy in idiopathic pulmonary fibrosis; an alarming press release. Eur Respir J 2012;39:805-6
25. Carroll J. Novartis cropping 371 research jobs in global R&D shakeup. Available from: Http://www.fiercebiotech.com/ story/novartis-chopping-371- researchjobs-global-rd-reorganization/2013-11-05 [Last accessed 23 November 2013]
26. Stockley R, Snell N, Donovan L, et al. Effects of AZD9056, a P2X7 antagonist, in patients with chronic obstructive pulmonary disease. Thorax 2008;63(Suppl VIII):A41-2
27. Miao Z, Wang Y, Manmohan L, et al. The CCR4 antagonist CCX6239 for the treatment of allergic airways disease. Eur Respir J 2013;42:725s
28. Pavord I, De Soyza A, Elborn J, et al. Efficacy and safety of AZD5069, a CXCR2 antagonist, in adult bronchiectasis. Eur Respir J 2013;42:331s-2s
29. Kilty I, Clarke N, Fairmain D, et al. PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease. Eur Respir J 2013;42:344s
30. Macnee W, Allan R, Jones I, et al. Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: A randomised clinical trial. Thorax 2013;68:738-45
31. Experimental asthma drug fails in midstage study. Medscape; Available from: Www.medscape.com [Last accessed 26 August 2013]
32. Compton C, McBryan D, Bucchioni E, Patalano F. The Novartis view on emerging drugs and novel targets for the treatment of chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2013;26:562-73
33. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455-66
34. Franciosi L, Diamant Z, Banner K, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: Findings from four clinical trials. Lancet Respir Med 2013;1:714-27